MA27500A1 - PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - Google Patents
PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASEInfo
- Publication number
- MA27500A1 MA27500A1 MA28329A MA28329A MA27500A1 MA 27500 A1 MA27500 A1 MA 27500A1 MA 28329 A MA28329 A MA 28329A MA 28329 A MA28329 A MA 28329A MA 27500 A1 MA27500 A1 MA 27500A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitor
- alzheimer
- disease
- prevention
- treatment
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 abstract 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 abstract 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 abstract 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 abstract 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 abstract 1
- 229940121773 Secretase inhibitor Drugs 0.000 abstract 1
- 239000003613 bile acid Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
L'invention a pour objet l'application des inhibiteurs de recapture intestinale de l'acide biliaire pour la prévention et le traitement de la maladie d'Alzheimer, le cas échéant en association avec un inhibiteur de HMG-CoA réductase, un inhibiteur de la capture de cholestérol, un inhibiteur de la synthèse de cholestérol ou un inhibiteur des APP secrétases.The subject of the invention is the application of inhibitors of intestinal reuptake of bile acid for the prevention and treatment of Alzheimer's disease, where appropriate in combination with an inhibitor of HMG-CoA reductase, an inhibitor of cholesterol capture, a cholesterol synthesis inhibitor or an APP secretase inhibitor.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215722A FR2848452B1 (en) | 2002-12-12 | 2002-12-12 | APPLICATION OF INTESTINAL BILIARY ACID RECAPTURE INHIBITORS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27500A1 true MA27500A1 (en) | 2005-08-01 |
Family
ID=32338722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28329A MA27500A1 (en) | 2002-12-12 | 2005-06-10 | PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1572174A1 (en) |
| JP (1) | JP2006514063A (en) |
| KR (1) | KR20050084250A (en) |
| CN (1) | CN1726016A (en) |
| AR (1) | AR042354A1 (en) |
| AU (1) | AU2003296802A1 (en) |
| BR (1) | BR0317280A (en) |
| CA (1) | CA2507945A1 (en) |
| CO (1) | CO5700712A2 (en) |
| FR (1) | FR2848452B1 (en) |
| HR (1) | HRP20050534A2 (en) |
| MA (1) | MA27500A1 (en) |
| MX (1) | MXPA05005556A (en) |
| NO (1) | NO20053341L (en) |
| NZ (1) | NZ540496A (en) |
| PE (1) | PE20040770A1 (en) |
| PL (1) | PL377110A1 (en) |
| RS (1) | RS20050420A (en) |
| RU (1) | RU2005121909A (en) |
| TW (1) | TW200503707A (en) |
| WO (1) | WO2004062652A1 (en) |
| ZA (1) | ZA200504656B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| ZA200603165B (en) | 2003-11-03 | 2007-07-25 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| CN1918131B (en) | 2004-02-05 | 2011-05-04 | 前体生物药物股份公司 | Novel inhibitors of glutaminyl cyclase |
| CA2589102C (en) | 2004-11-02 | 2013-08-13 | Northwestern University | Pyridazine compounds and methods for using the compounds to treat inflammatory diseases |
| CA2650711A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| NZ581099A (en) * | 2007-05-22 | 2012-03-30 | Otsuka Pharma Co Ltd | A medicament comprising a carbostyril derivative and donepezil for treating Alzheimer's disease |
| JP6217938B2 (en) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | Bile acid recirculation inhibitors for the treatment of cholestatic liver disease in children |
| CA2852957C (en) * | 2011-10-28 | 2020-08-04 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2040996A1 (en) * | 1990-05-02 | 1991-11-03 | Robert L. Albright | Composition and method for controlling cholesterol |
| EP0572560B1 (en) * | 1991-02-22 | 2003-01-29 | SHAPIRO, Howard, K. | Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| US6383500B1 (en) * | 1996-06-27 | 2002-05-07 | Washington University | Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| JP2002501887A (en) * | 1998-01-28 | 2002-01-22 | ワーナー−ランバート・カンパニー | How to treat Alzheimer's disease |
| US6080778A (en) * | 1998-03-23 | 2000-06-27 | Children's Medical Center Corporation | Methods for decreasing beta amyloid protein |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19825804C2 (en) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds |
| DE19845405C2 (en) * | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Aryl-substituted propanolamine derivatives and their use |
| AU2001233299A1 (en) * | 2000-02-04 | 2001-08-14 | Esperion Therapeutics Inc. | Methods for treating alzheimer's disease |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| SE0104334D0 (en) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
-
2002
- 2002-12-12 FR FR0215722A patent/FR2848452B1/en not_active Expired - Fee Related
-
2003
- 2003-12-10 CN CNA2003801059727A patent/CN1726016A/en active Pending
- 2003-12-10 AU AU2003296802A patent/AU2003296802A1/en not_active Abandoned
- 2003-12-10 RU RU2005121909/15A patent/RU2005121909A/en not_active Application Discontinuation
- 2003-12-10 PE PE2003001247A patent/PE20040770A1/en not_active Application Discontinuation
- 2003-12-10 AR ARP030104540A patent/AR042354A1/en not_active Application Discontinuation
- 2003-12-10 NZ NZ540496A patent/NZ540496A/en unknown
- 2003-12-10 KR KR1020057010595A patent/KR20050084250A/en not_active Withdrawn
- 2003-12-10 MX MXPA05005556A patent/MXPA05005556A/en not_active Application Discontinuation
- 2003-12-10 CA CA002507945A patent/CA2507945A1/en not_active Abandoned
- 2003-12-10 BR BR0317280-5A patent/BR0317280A/en not_active IP Right Cessation
- 2003-12-10 PL PL377110A patent/PL377110A1/en not_active Application Discontinuation
- 2003-12-10 WO PCT/FR2003/003654 patent/WO2004062652A1/en not_active Ceased
- 2003-12-10 RS YUP-2005/0420A patent/RS20050420A/en unknown
- 2003-12-10 HR HR20050534A patent/HRP20050534A2/en not_active Application Discontinuation
- 2003-12-10 JP JP2004566119A patent/JP2006514063A/en not_active Abandoned
- 2003-12-10 EP EP03815109A patent/EP1572174A1/en not_active Withdrawn
- 2003-12-11 TW TW092134949A patent/TW200503707A/en unknown
-
2005
- 2005-06-07 ZA ZA200504656A patent/ZA200504656B/en unknown
- 2005-06-09 CO CO05056010A patent/CO5700712A2/en not_active Application Discontinuation
- 2005-06-10 MA MA28329A patent/MA27500A1/en unknown
- 2005-07-08 NO NO20053341A patent/NO20053341L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO5700712A2 (en) | 2006-11-30 |
| HRP20050534A2 (en) | 2006-11-30 |
| AU2003296802A1 (en) | 2004-08-10 |
| AR042354A1 (en) | 2005-06-15 |
| BR0317280A (en) | 2005-11-08 |
| RU2005121909A (en) | 2006-01-20 |
| WO2004062652A1 (en) | 2004-07-29 |
| FR2848452B1 (en) | 2007-04-06 |
| ZA200504656B (en) | 2006-08-30 |
| NO20053341D0 (en) | 2005-07-08 |
| EP1572174A1 (en) | 2005-09-14 |
| FR2848452A1 (en) | 2004-06-18 |
| JP2006514063A (en) | 2006-04-27 |
| NO20053341L (en) | 2005-09-07 |
| RS20050420A (en) | 2007-04-10 |
| KR20050084250A (en) | 2005-08-26 |
| CA2507945A1 (en) | 2004-07-29 |
| PL377110A1 (en) | 2006-01-23 |
| PE20040770A1 (en) | 2004-12-10 |
| NZ540496A (en) | 2008-04-30 |
| TW200503707A (en) | 2005-02-01 |
| CN1726016A (en) | 2006-01-25 |
| MXPA05005556A (en) | 2005-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN01125A1 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING A CETP AND ATORVASTATIN INHIBITOR | |
| GB0223040D0 (en) | Therapeutic compounds | |
| EP1643986A4 (en) | PHENYLCARBOXYLATE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| SI1509232T1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
| EP1604664A4 (en) | MEDICINE FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND HYPERTENSION | |
| WO2005004802A3 (en) | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease | |
| TNSN98155A1 (en) | COMBINATIONS OF PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN AND ANTIHYPERTENSITIVE AGENTS, AND PROCESS FOR THEIR PREPARATION | |
| EP1910829A4 (en) | PREVENTION AND TREATMENT OF SYNUCLEINOPATHIC AND AMYLOIDOGENIC DISEASE | |
| EP1899486A4 (en) | METHOD OF IDENTIFICATION, EVALUATION AND TREATMENT OF PATIENTS FOLLOWING ANTICANCER TREATMENT | |
| ATE350375T1 (en) | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES | |
| FR2840804B1 (en) | SYSTEM FOR THE TREATMENT OF OBESITY AND IMPLANT FOR SUCH A SYSTEM | |
| EP1656359A4 (en) | MACROCYCLIC BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| EP1771201A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF OXALATE-RELATED DISEASE | |
| IL229124A0 (en) | Inhibitors of the mutant form of kit | |
| MY133332A (en) | Pyrrolidone derivatives as maob inhibitors | |
| NO20053855L (en) | 1-Phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases. | |
| AU2003231252A1 (en) | Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease | |
| MA27500A1 (en) | PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE | |
| NO20065117L (en) | Composition comprising a JNK inhibitor and cyclosporin. | |
| MXPA05009986A (en) | Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders. | |
| WO2002039122A3 (en) | Methods for the identification and the treatment of cardiovascular disease | |
| EP1488808A4 (en) | MEANS FOR THE TREATMENT OF GLOMERULAR DISEASES | |
| ATE423102T1 (en) | 4-SUBSTITUTED-5-CYANO-1H-PYRIMIDINE-6-(TH)IONES AS A GSK-3 INHIBITOR | |
| EP1726313A4 (en) | MEDICINE FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS | |
| EP1669085A4 (en) | THERAPEUTIC AGENT FOR THE PREVENTION AND / OR TREATMENT OF ALZHEIMER'S DISEASE |